Fractyl Health Survey Finds 33% of GLP-1 Users Prefer One-Time Procedure Over Continued Medication

PUBT · 3d ago
Fractyl Health Survey Finds 33% of GLP-1 Users Prefer One-Time Procedure Over Continued Medication
  • Fractyl Health announced market research showing 33% of nearly 300 surveyed GLP-1 users preferred a one-time procedure, supporting investigational Revita commercialization planning.
  • An estimated one million US patients discontinue GLP-1 medications monthly, creating potential demand for weight-maintenance treatments.
  • Previously reported six-month REMAIN-1 results showed Revita helped preserve most GLP-1-induced weight loss, meeting its primary endpoint against sham treatment.
  • No device- or procedure-related serious adverse events were reported through September 24, 2026.
  • Twelve-month pivotal trial results, including a second primary endpoint, are expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290700PRIMZONEFULLFEED9855863) on October 29, 2026, and is solely responsible for the information contained therein.